New antibody aims to neutralize allergies by clearing IgE
NCT ID NCT07701954
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental antibody drug called LCA-0061, designed to target and remove immunoglobulin E (IgE), a key driver of allergic reactions. The study first evaluates safety and tolerability in healthy people with elevated IgE levels, then in people with peanut allergy. Researchers are looking at how the drug moves through the body and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an antibody-based drug called LCA-0061 that targets and clears immunoglobulin E (IgE)
- What this could lead to
- If successful, this could lead to a new treatment for peanut allergy and other allergic conditions by lowering IgE levels.
- What could go wrong
- This is an early Phase 1 trial focused on safety, so it is too soon to know if the drug will effectively treat allergies. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: Part A (SAD) and Part B (MAD) 1. Must provide written consent for participation 2. Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2 (inclusive) and body weight ≥ 50kg at screening 3. Have elevated serum IgE at screening 4. Female participants of childbearing potential or male participants capable of fathering a child must be willing to use highly effective methods of contraception throughout the study and for at least 30 days after the last dose of the investigational product. Part A Only 1.Must be otherwise healthy with history of atopy defined as one or more of the following: history of positive skin tests to common allergens, allergic conjunctivitis, food allergy, atopic dermatitis, urticaria Part B Only 1. Be otherwise healthy with history of peanut allergy 2. Elevated peanut-specific serum IgE within 6 months of screening 3. Have positive skin prick test (SPT) to peanuts at screening Key Exclusion Criteria: Part A and B 1. Pregnant or lactating 2. History of clinically relevant underlying comorbidities including: 1. chronic obstructive pulmonary disease 2. myocardial infarction 3. chronic heart failure or unstable angina pectoris 4. hyperlipidemia 5. liver disease or known hepatic or biliary abnormalities \[except Gilbert's disease or asymptomatic gallstones\] 6. autoimmune or connective tissue disease 7. chronic inflammatory disease 8. persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals 9. poorly controlled atopic dermatitis requiring treatment with phototherapy, systemic immunosuppressants, or immunomodulators 10. Poorly controlled asthma 11. poorly controlled hypertension 3. clinically significant abnormal electrocardiogram or laboratory tests (hematology, clinical chemistries, liver function tests, lipid panel, serology, or urinalysis) at screening 4. Currently receiving immunotherapy for food allergies 5. Use of nicotine containing products (excluding nicotine patches or gum for smoking cessation) within 6 months prior to screening. 6. Positive test for alcohol or illicit drugs at screening or prior to dosing. 7. Other conditions or concomitant medications that are excluded by the protocol, or in the opinion of the investigator, or sponsor representative, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CAN001
RECRUITINGMississauga, Ontario, L4W 1N2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection raise the peanut allergy safety threshold?
- Can a simple blood test pinpoint peanut allergy?
- A spoonful of nuts? trial tests Multi-Allergy desensitization in kids
- New blood test could make allergy diagnosis faster and easier
- Mali allergy study seeks clues in gut and skin germs
- Food allergy treatment: how do kids fare years later?